Results 171 to 180 of about 791,647 (284)
Summary Immune dysfunction is implicated in the aetiology of Hodgkin lymphoma (HL), but the association between inborn errors of immunity (IEI) and HL remains poorly understood. We conducted a retrospective, register‐based case–control study in Sweden over five decades to investigate the relationship between IEI and HL. Individuals diagnosed with HL in
Agnes Winsa +7 more
wiley +1 more source
Role of <sup>18</sup>F-FDG PET/CT in the diagnosis and treatment response assessment of primary pulmonary lymphoma. [PDF]
Pu Y +11 more
europepmc +1 more source
Summary Using LYmphoma Study Association clinical trials combining 438 first‐line large B‐cell lymphomas (LBCL) patients >80 years old, we defined SENIOR‐IPI, an easily applicable prognostic index for this elderly population treated with an anti‐CD20‐miniCHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)‐based regimen.
Sydney Dubois +8 more
wiley +1 more source
Case Report: Primary pulmonary lymphoma with CT negative and PET high metabolism combined with hemophagocytic syndrome. [PDF]
Dang N +6 more
europepmc +1 more source
TKI treatment promotes mitochondrial fission and metabolic reprogramming toward oxidative phosphorylation in residual EGFR‐mutant lung cancer cells. Targeting this metabolic vulnerability restores TKI sensitivity and provides a promising strategy to overcome acquired resistance.
Yu Zhao +8 more
wiley +1 more source
Characteristics of pulmonary lymphoma on baseline <sup>18</sup>F-FDG positron emission tomography/computed tomography and their clinical value in predicting treatment response. [PDF]
Cheng R +5 more
europepmc +1 more source
Primary pulmonary AIDS-related lymphoma
Extranodal involvement is common in lymphomas associated with human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS).
Schtirbu, Ricardo +4 more
core
Algorithms in Allergy: Treatment of Hypereosinophilic Syndromes, 2026 Update
Allergy, EarlyView.
Guillaume Lefèvre +5 more
wiley +1 more source
WJOG14120L NESSIE evaluated cisplatin, gemcitabine, and necitumumab (CGN) as second‐line therapy after ICI‐based treatment in 46 patients with advanced squamous NSCLC. ORR was 26.1%, DCR 87.0%, and median PFS 4.4 months. Although the predefined ORR threshold was not met, CGN showed modest antitumor activity with manageable toxicity.
Hiroshige Yoshioka +15 more
wiley +1 more source
Primary pulmonary lymphoma: a surgical series. [PDF]
Otero Lozano D +7 more
europepmc +1 more source

